Skip to main content
Top
Published in: Cardiovascular Intervention and Therapeutics 1/2022

01-01-2022 | Clopidogrel | Original Article

Temporal trends in coronary intervention strategies and the impact on one-year clinical events: data from a Japanese multi-center real-world cohort study

Authors: Kenji Sakamoto, Ryota Sato, Noriaki Tabata, Masanobu Ishii, Takayoshi Yamashita, Suguru Nagamatsu, Kota Motozato, Kenshi Yamanaga, Seiji Hokimoto, Daisuke Sueta, Satoshi Araki, Koichiro Fujisue, Yuichiro Arima, Seiji Takashio, Kazuteru Fujimoto, Hideki Shimomura, Ryusuke Tsunoda, Toyoki Hirose, Koji Sato, Koichi Kikuta, Naritsugu Sakaino, Shinichi Nakamura, Nobuyasu Yamamoto, Toshiyuki Matsumura, Ichiro Kajiwara, Shinji Tayama, Tomohiro Sakamoto, Koichi Nakao, Shuichi Oshima, Eiichiro Yamamoto, Koichi Kaikita, Kenichi Tsujita, The Kumamoto Intervention Conference Study (KICS) Investigators

Published in: Cardiovascular Intervention and Therapeutics | Issue 1/2022

Login to get access

Abstract

Percutaneous coronary intervention (PCI) has significantly advanced over the last 40 years, but it is not clear whether there have been any changes in prognosis in recent years. The Kumamoto Intervention Conference Study Real-World Registry is a multi-center registry that enrolls consecutive patients undergoing PCI in 17 centers in Kyushu, Japan. To elucidate the clinical impact of recent changes in treatment strategies, 8841 consecutive participants (historical PCI: n = 4038, enrolled between January 2013 and December 2014, and current PCI: n = 4803, between January 2015 and March 2017) with 1-year follow-up data were analyzed. The incidences of major adverse cardiovascular and other clinical events were comparable between historical PCI and current PCI, even though complex lesions were more frequent during the more recent period. During this period, the use of radial approaches, drug eluting stents, and coronary imaging was greater. The use of prasugrel was more frequent (P < 0.001) during the time periods. Comparable event rates were associated with the use of clopidogrel (52.7%) and prasugrel (47.3%). In the sub-analysis for acute coronary syndrome (n = 5047), similar clinical event rates were recorded for historical and current PCI. Although the lesions to be treated are becoming more severe and complex, equivalent clinical outcomes have been maintained in recent years, possibly due to advances in the devices and medication used.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979;301:61–8.CrossRef Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979;301:61–8.CrossRef
2.
go back to reference Schatz RA, Baim DS, Leon M, Ellis SG, Goldberg S, Hirshfeld JW, et al. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation. 1991;83:148–61.CrossRef Schatz RA, Baim DS, Leon M, Ellis SG, Goldberg S, Hirshfeld JW, et al. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation. 1991;83:148–61.CrossRef
3.
go back to reference Stone GW, Brodie BR, Griffin JJ, Costantini C, Morice MC, St Goar FG, et al. Clinical and angiographic follow-Up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation. 1999;99:1548–54.CrossRef Stone GW, Brodie BR, Griffin JJ, Costantini C, Morice MC, St Goar FG, et al. Clinical and angiographic follow-Up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation. 1999;99:1548–54.CrossRef
4.
go back to reference Saito Y and Kobayashi Y. Contemporary coronary drug-eluting and coated stents: a mini-review. Cardiovasc Interv Ther. 2020. Saito Y and Kobayashi Y. Contemporary coronary drug-eluting and coated stents: a mini-review. Cardiovasc Interv Ther. 2020.
5.
go back to reference Mintz GS. Intravascular ultrasound guidance improves patient survival (mortality) after drug-eluting stent implantation: review and updated bibliography. Cardiovasc Interv Ther. 2020;35:37–43.CrossRef Mintz GS. Intravascular ultrasound guidance improves patient survival (mortality) after drug-eluting stent implantation: review and updated bibliography. Cardiovasc Interv Ther. 2020;35:37–43.CrossRef
6.
go back to reference Barath P, Fishbein MC, Vari S, Forrester JS. Cutting balloon: a novel approach to percutaneous angioplasty. Am J Cardiol. 1991;68:1249–52.CrossRef Barath P, Fishbein MC, Vari S, Forrester JS. Cutting balloon: a novel approach to percutaneous angioplasty. Am J Cardiol. 1991;68:1249–52.CrossRef
7.
go back to reference Safian RD, Feldman T, Muller DW, Mason D, Schreiber T, Haik B, et al. Coronary angioplasty and Rotablator atherectomy trial (CARAT): immediate and late results of a prospective multicenter randomized trial. Catheter Cardiovasc Interv. 2001;53:213–20.CrossRef Safian RD, Feldman T, Muller DW, Mason D, Schreiber T, Haik B, et al. Coronary angioplasty and Rotablator atherectomy trial (CARAT): immediate and late results of a prospective multicenter randomized trial. Catheter Cardiovasc Interv. 2001;53:213–20.CrossRef
8.
go back to reference Jolly SS, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011;377:1409–20.CrossRef Jolly SS, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011;377:1409–20.CrossRef
9.
go back to reference Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–16.CrossRef Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–16.CrossRef
10.
go back to reference Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015;66:495–507.CrossRef Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015;66:495–507.CrossRef
11.
go back to reference Kaikita K, Yoshimura H, Ishii M, Kudoh T, Yamada Y, Yamamoto E, et al. Tailored adjunctive cilostazol therapy based on CYP2C19 genotyping in patients with acute myocardial infarction—the CALDERA-GENE study. Circ J. 2018;82:1517–25.CrossRef Kaikita K, Yoshimura H, Ishii M, Kudoh T, Yamada Y, Yamamoto E, et al. Tailored adjunctive cilostazol therapy based on CYP2C19 genotyping in patients with acute myocardial infarction—the CALDERA-GENE study. Circ J. 2018;82:1517–25.CrossRef
12.
go back to reference Head SJ, Davierwala PM, Serruys PW, Redwood SR, Colombo A, Mack MJ, et al. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. Eur Heart J. 2014;35:2821–30.CrossRef Head SJ, Davierwala PM, Serruys PW, Redwood SR, Colombo A, Mack MJ, et al. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. Eur Heart J. 2014;35:2821–30.CrossRef
13.
go back to reference Authors/Task Force m, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, et al. ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619.CrossRef Authors/Task Force m, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, et al. ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619.CrossRef
14.
go back to reference De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, et al. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. 2014;371:1208–17.CrossRef De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, et al. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. 2014;371:1208–17.CrossRef
15.
go back to reference Zhang J, Gao X, Kan J, Ge Z, Han L, Lu S, et al. Intravascular ultrasound versus angiography-guided drug-eluting stent implantation: the ULTIMATE trial. J Am Coll Cardiol. 2018;72:3126–37.CrossRef Zhang J, Gao X, Kan J, Ge Z, Han L, Lu S, et al. Intravascular ultrasound versus angiography-guided drug-eluting stent implantation: the ULTIMATE trial. J Am Coll Cardiol. 2018;72:3126–37.CrossRef
16.
go back to reference Yamashita T, Sakamoto K, Tabata N, Ishii M, Sato R, Nagamatsu S, et al. Imaging-guided PCI for event suppression in Japanese acute coronary syndrome patients: community-based observational cohort registry. Cardiovasc Interv Ther. 2020. Yamashita T, Sakamoto K, Tabata N, Ishii M, Sato R, Nagamatsu S, et al. Imaging-guided PCI for event suppression in Japanese acute coronary syndrome patients: community-based observational cohort registry. Cardiovasc Interv Ther. 2020.
17.
go back to reference Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet. 2013;382:1638–45.CrossRef Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet. 2013;382:1638–45.CrossRef
18.
go back to reference Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med. 2015;372:1389–98.CrossRef Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med. 2015;372:1389–98.CrossRef
19.
go back to reference Lagerqvist B, Frobert O, Olivecrona GK, Gudnason T, Maeng M, Alstrom P, et al. Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med. 2014;371:1111–20.CrossRef Lagerqvist B, Frobert O, Olivecrona GK, Gudnason T, Maeng M, Alstrom P, et al. Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med. 2014;371:1111–20.CrossRef
20.
go back to reference Kimura E, Kishida H. Treatment of variant angina with drugs: a survey of 11 cardiology institutes in Japan. Circulation. 1981;63:844–8.CrossRef Kimura E, Kishida H. Treatment of variant angina with drugs: a survey of 11 cardiology institutes in Japan. Circulation. 1981;63:844–8.CrossRef
21.
go back to reference Nishigaki K, Inoue Y, Yamanouchi Y, Fukumoto Y, Yasuda S, Sueda S, et al. Prognostic effects of calcium channel blockers in patients with vasospastic angina–a meta-analysis. Circ J. 2010;74:1943–50.CrossRef Nishigaki K, Inoue Y, Yamanouchi Y, Fukumoto Y, Yasuda S, Sueda S, et al. Prognostic effects of calcium channel blockers in patients with vasospastic angina–a meta-analysis. Circ J. 2010;74:1943–50.CrossRef
22.
go back to reference Iqbal J, Zhang YJ, Holmes DR, Morice MC, Mack MJ, Kappetein AP, et al. Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the synergy between percutaneous coronary intervention with TAXUS and cardiac surgery (SYNTAX) trial at the 5-year follow-up. Circulation. 2015;131:1269–77.CrossRef Iqbal J, Zhang YJ, Holmes DR, Morice MC, Mack MJ, Kappetein AP, et al. Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the synergy between percutaneous coronary intervention with TAXUS and cardiac surgery (SYNTAX) trial at the 5-year follow-up. Circulation. 2015;131:1269–77.CrossRef
23.
go back to reference Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27:1166–73.CrossRef Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27:1166–73.CrossRef
24.
go back to reference Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153(66):e9-16. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153(66):e9-16.
25.
go back to reference Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371:1353–63.CrossRef Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371:1353–63.CrossRef
26.
go back to reference Natsuaki M, Morimoto T, Yamaji K, Watanabe H, Yoshikawa Y, Shiomi H, et al. Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores. J Am Heart Assoc. 2018;7. Natsuaki M, Morimoto T, Yamaji K, Watanabe H, Yoshikawa Y, Shiomi H, et al. Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores. J Am Heart Assoc. 2018;7.
27.
go back to reference Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735–49.CrossRef Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735–49.CrossRef
28.
go back to reference Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, et al. Coronary thrombosis and major bleeding after pci with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol. 2016;67:2224–34.CrossRef Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, et al. Coronary thrombosis and major bleeding after pci with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol. 2016;67:2224–34.CrossRef
29.
go back to reference Ohya M, Shimada T, Osakada K, Kuwayama A, Miura K, Murai R, et al. In-hospital bleeding and utility of a maintenance dose of prasugrel 2.5 mg in high bleeding risk patients with acute coronary syndrome. Circ J. 2018;82:1874–83.CrossRef Ohya M, Shimada T, Osakada K, Kuwayama A, Miura K, Murai R, et al. In-hospital bleeding and utility of a maintenance dose of prasugrel 2.5 mg in high bleeding risk patients with acute coronary syndrome. Circ J. 2018;82:1874–83.CrossRef
30.
go back to reference Wakabayashi S, Ariyoshi N, Kitahara H, Fujii K, Fujimoto Y, Kobayashi Y. Efficacy of 2.5-mg prasugrel in elderly or low-body-weight patients. Circ J. 2018;82:2326–31.CrossRef Wakabayashi S, Ariyoshi N, Kitahara H, Fujii K, Fujimoto Y, Kobayashi Y. Efficacy of 2.5-mg prasugrel in elderly or low-body-weight patients. Circ J. 2018;82:2326–31.CrossRef
Metadata
Title
Temporal trends in coronary intervention strategies and the impact on one-year clinical events: data from a Japanese multi-center real-world cohort study
Authors
Kenji Sakamoto
Ryota Sato
Noriaki Tabata
Masanobu Ishii
Takayoshi Yamashita
Suguru Nagamatsu
Kota Motozato
Kenshi Yamanaga
Seiji Hokimoto
Daisuke Sueta
Satoshi Araki
Koichiro Fujisue
Yuichiro Arima
Seiji Takashio
Kazuteru Fujimoto
Hideki Shimomura
Ryusuke Tsunoda
Toyoki Hirose
Koji Sato
Koichi Kikuta
Naritsugu Sakaino
Shinichi Nakamura
Nobuyasu Yamamoto
Toshiyuki Matsumura
Ichiro Kajiwara
Shinji Tayama
Tomohiro Sakamoto
Koichi Nakao
Shuichi Oshima
Eiichiro Yamamoto
Koichi Kaikita
Kenichi Tsujita
The Kumamoto Intervention Conference Study (KICS) Investigators
Publication date
01-01-2022
Publisher
Springer Singapore
Published in
Cardiovascular Intervention and Therapeutics / Issue 1/2022
Print ISSN: 1868-4300
Electronic ISSN: 1868-4297
DOI
https://doi.org/10.1007/s12928-020-00752-5

Other articles of this Issue 1/2022

Cardiovascular Intervention and Therapeutics 1/2022 Go to the issue